
CGRP and Migraine: The Molecule and the New Drugs
What CGRP is, how it drives an attack, and how antibodies and gepants block it.

What CGRP is, how it drives an attack, and how antibodies and gepants block it.

A quick reference chart of every CGRP medication, its target, dose and use.

In one study, 70% on CGRP antibodies became super-responders, many only after 6 months.

Among people whose migraine days fell by half in the first month on atogepant (Qulipta), most kept that response through month 3, and most month-4 responders…

In a 545-person head-to-head trial, fewer people stopped atogepant (Qulipta) because of side effects than topiramate (Topamax), and more had their migraine days cut in half.

In 5,438 people given CGRP antibody injections in Catalonia's public health system, about half of treatment courses cut headache days at least in half by 3…

A real-world study followed 57 people who only partly responded to eptinezumab (Vyepti) 100 mg. After moving up to 300 mg, about two in three reached…

In 96 adults starting a CGRP antibody or Botox, people whose migraine responded reported a bigger improvement in memory and concentration complaints than people whose migraine…

In 191 people who logged 377 migraine attacks, rimegepant (Nurtec ODT) gave pain freedom at 2 hours in 45% of attacks. For most people, the response…

A 6,361-patient study found CGRP migraine preventives did not raise blood pressure faster than in similar patients not taking them. Atogepant (Qulipta) users also lost the…

A JAMA Neurology study of 7,579 pregnancies linked CGRP antibody injections in early pregnancy to a higher miscarriage rate. Propranolol showed no link, which matters for…

A 2026 review gathered every published report of hair loss on CGRP antibodies and gepants. The signal is consistent across the class, the hair loss is…

A meta-analysis of 53 real-world studies found about three in four people were still on an anti-CGRP therapy at one year. Most who stopped did so…

A 25-trial analysis ranked Excedrin-type combos and ibuprofen above gepants for 2-hour pain relief.

A review of 16 studies on CGRP drugs during periods, pregnancy, breastfeeding and birth control.

The AAN and AHS prevention guideline gives four drug lists instead of naming a single best drug.

Six trials and 3,453 people show how much atogepant cuts migraine days and which dose works best.

A review of 16 trials compares atogepant and rimegepant for preventing and stopping attacks.

Real-world data on every-other-day rimegepant for prevention and why starting earlier helps.

In a one-year study of nearly 600 people on atogepant, average weight went down.

A 19-trial meta-analysis looks at whether CGRP preventives like erenumab raise blood pressure.

Real-world data show fremanezumab cut migraine days by nearly 6 a month.

Blood CGRP was lower in people with migraine, not higher, and did not track with attacks.

What CGRP is, how it drives an attack, and how antibodies and gepants block it.

In over 4,300 patients, CGRP antibodies stayed well tolerated past a year of treatment.

A step-by-step hospital protocol for people who had a hypersensitivity reaction to Vyepti.

In one study, 70% on CGRP antibodies became super-responders, many only after 6 months.

Real-world side effect data for Aimovig, Ajovy, Emgality and Vyepti in one chart.

People who also used triptans responded better to CGRP antibodies in a 336-patient study.

Practical steps to reduce skin reactions to CGRP injections and keep treatment going.

Real-world data on 14,285 patients found CGRP antibodies safe, with a few signals to watch.


A trial tested fremanezumab (Ajovy) in people with both migraine and major depression.

A quick reference chart of every CGRP medication, its target, dose and use.

Which patient traits predicted a good response to erenumab (Aimovig) in one study.

In real-world use, atogepant cut migraine days by more than half, even after other failures.

A three-year study suggests CGRP antibodies may change the course of migraine.

Early trials of Lu AG09222, an antibody against PACAP, show promise for prevention.

Real-world data on the side effects people report with gepants.

Sildenafil triggered attacks even with CGRP blocked, pointing to a cGMP pathway.

In one study, about 3% on CGRP antibodies had ECG changes or heart-related events.

Why CGRP is a promising but tricky blood marker for diagnosing and tracking migraine.

How long to try a CGRP antibody before deciding whether it works for you.

The AHS now says CGRP-targeting treatments can be a first-line option for prevention.

Key takeaways from Peter Goadsby on CGRP and the biochemistry of migraine.

What PACAP is, how it drives migraine, and where PACAP-targeting drugs stand.

Clinical Features VS Anti-CGRP Treatment Response

CGRP antibodies may not reduce aura itself but may reduce the headache that follows.

Will I Respond Again To Anti-CGRP Monoclonal Antibody Therapy?

FDA Approves Zavzpret (zavegepant), a New Nasal Spray to Treat Acute Migraine